Clinical Research and Trial Infrastructure in South-East Asia (Malaysia)

Abstract

Abstract Malaysia is situated in the South East Asia region with population of 32.5milion. We comprises of multiple ethnicity with the Malay (68.6%), Chinese (23.4%), Indian (7%) and others (1%). The total number of death in 2016 were 154,000 with 74% deaths from non-communicable disease and cancer contributed to 16% of total death cases. The 10 most common cancer in Malaysia are breast cancers, followed by colorectal, lungs, lymphomas, nasopharynx, leukaemia, cervix uteri, liver, ovary and stomach. The top 5 most common cancers in male are colorectal cancers followed by lungs, prostate, nasopharynx and liver. The top 5 mos common cancers in female are breast cancers followed by colorectal, cervix uteri, lungs and ovary. There are huge opportunity to conduct clinical trials in Malaysia with over 100 clinical trial sites in Malaysia. Average cost per patient per visit is USD350. We are also partnering with multiple clinical research organization - Cancer Research Malaysia, IQVIA, Parexel and so many more. The clinical trial infrastructure in Malaysia is non-inferior comparing to developed countries with adequate number of patients. The lecture will discuss further in the clinical trial set-up in Malaysia.